Biological Screening of Novel Structural Analog of Celecoxib as Potential Anti-Inflammatory and Analgesic Agent

Medicina (Kaunas). 2019 Apr 5;55(4):93. doi: 10.3390/medicina55040093.

Abstract

Background and objectives: The clinical use of non-steroidal anti-inflammatory drugs is limited due to high incidence of adverse drug reactions. The pyrrole heterocycle is included in the chemical structure of a number of drugs with various activities and shows relatively good tolerability and safety. The objectives of our study were to evaluate the analgesic and anti-inflammatory activity, as well as possible organ toxicity, of 2-[3-acetyl-5-(4-chloro-phenyl)-2-methyl-pyrrol-1-yl]-3-(1H-indol-3-yl)-propionic acid (compound 3g), a novel N-pyrrolylcarboxylic acid structurally similar to celecoxib. Materials and methods: All experiments were performed on 6-week-old male Wistar rats divided into parallel groups (n = 8). Antinociception was assessed using animal pain models with thermal and chemical stimuli (paw withdrawal, tail-flick, and formalin tests). Criteria for the analgesic effect were increased latency in the paw withdrawal and tail-flick tests and decreased paw licking time in the formalin test compared to animals treated with saline (control). Anti-inflammatory activity was measured using a carrageenan-induced paw edema model; the criterion for anti-inflammatory effect was decreased edema compared to control. Blood samples were obtained after animals were sacrificed to assess possible organ toxicity. Statistical analysis was performed with IBM SPSS 20.0. Results: 2-[3-Acetyl-5-(4-chloro-phenyl)-2-methyl-pyrrol-1-yl]-3-(1H-indol-3-yl)-propionic acid had analgesic action against chemical stimulus after single and multiple administration and against thermal stimulus after single administration. Compound 3g significantly suppressed carrageenan-induced paw edema after both single and continuous administration. After continuous administration, hematological tests showed that compound 3g decreased leukocyte and platelet levels and elevated serum creatinine levels. Conclusions: Antinociception with the tested compound is most likely mediated by spinal, peripheral, and anti-inflammatory mechanisms. Possible tolerance of the analgesic action at the spinal level develops after continuous administration. Anti-inflammatory activity is significant and probably the leading cause of antinociception. After multiple administration, compound 3g showed signs of potential nephrotoxicity and antiplatelet activity, as well as suppression of leukocyte levels.

Keywords: NSAIDs; carrageenan; celecoxib; formalin; plantar test; pyrrole; tail-flick.

MeSH terms

  • Analgesics / administration & dosage
  • Analgesics / adverse effects
  • Analgesics / chemistry*
  • Analgesics / pharmacology*
  • Analysis of Variance
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry*
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Behavior, Animal / drug effects
  • Blood Platelets / drug effects
  • Carrageenan / administration & dosage
  • Carrageenan / pharmacology
  • Celecoxib / administration & dosage
  • Celecoxib / adverse effects
  • Celecoxib / analogs & derivatives*
  • Celecoxib / pharmacology*
  • Drug Evaluation, Preclinical*
  • Edema / chemically induced
  • Edema / drug therapy
  • Erythrocytes / drug effects
  • Hemoglobins / analysis
  • Indoles / chemistry*
  • Indoles / pharmacology*
  • Leukocytes / drug effects
  • Male
  • Models, Animal
  • Pain Measurement
  • Pyrroles / chemistry
  • Rats
  • Rats, Wistar

Substances

  • Analgesics
  • Anti-Inflammatory Agents, Non-Steroidal
  • Hemoglobins
  • Indoles
  • Pyrroles
  • Carrageenan
  • Celecoxib